CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
Carvediloldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04023110
NCT04023110Phase 1Completed
CompareCT.gov

A Pilot Study of Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Abramson Cancer Center at Penn Medicine·interventional·Posted Jul 17, 2019·Updated Oct 9, 2025

In Brief

A Phase 1 clinical trial evaluating Carvedilol for Cardiotoxicity and 5 related conditions. Completed, enrolled 68 participants across 1 site.

Detailed Summary

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), American Heart Association

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 17, 2019
Enrollment StartAug 9, 2019
Primary CompletionAug 31, 2024
Study CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.0 years ago

Interventions

Carvediloldrug

Individually dosed carvedilol